Benjamin Bell is an Analyst at Catalio Capital Management, LP.
Ben is currently a PhRMA Foundation Postdoctoral Fellow with the Johns Hopkins Drug Discovery center, where he leads the animal pharmacology components of several drug development efforts. His work evaluates therapeutic efficacy of novel compounds in mouse models of neurocognitive disorders, neuroinflammation, sleep dysfunction, and Alzheimer’s Disease.
He earned his Ph.D. from the Human Genetics program at the Johns Hopkins School of Medicine in 2019, for his work in Dr. Mark Wu’s lab on the molecular mechanisms of circadian regulation of sleep and arousal. Ben graduated with a B.S. in Biochemistry from Northeastern University in Boston, MA.